GlobeNewswire·May 22, 2026, 7:05 AM ET

Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

Assembly Biosciences priced an underwritten offering of 3,358,602 common stock shares at $26.50 per share.
Pre-funded warrants to purchase up to 415,000 shares were sold to certain investors at $26.499 per warrant.
Gross proceeds from the offering are expected to be approximately $100 million before deducting expenses.
Underwriters received a 30-day option to purchase an additional 566,040 shares of common stock.
Investors in the offering included Gilead Sciences, Commodore Capital, Farallon Capital Management, Seven Fleet Capital, Sirenia Capital Management LP, Columbia Threadneedle Investments, Paradigm BioCapital Advisors, Squadron Capital Management, a large global mutual fund, & other healthcare-dedicated investors.
The offering is expected to close on or about May 26, 2026, subject to customary closing conditions.
Net proceeds will fund clinical development of pipeline candidates & general corporate purposes.
Guggenheim Securities & UBS Investment Bank serve as joint book-running managers, while Mizuho acts as a book-running manager & H.C. Wainwright & Co. acts as the lead manager.
A shelf registration statement for the securities was filed with the SEC & declared effective on March 27, 2026.
Prospectus supplements will be filed with the SEC & available at www.sec.gov.
Assembly Biosciences focuses on developing small-molecule therapeutics for serious viral & liver diseases including HDV, HBV, herpesvirus, & cholestatic liver diseases.